Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

This is a non-randomized phase II trial of targeted radiotherapy (RT) administered
concurrently with panitumumab in patients with locally advanced squamous cell carcinoma of
the head and neck. This protocol addresses patients with medical comorbidities that make
them poor candidates for concurrent chemotherapy. Radiotherapy treatment will be directed
at disease visible on diagnostic imaging modalities and the ipsilateral hemi-neck, sparing
elective regions in the contralateral N0 hemi-neck with less than 20% chance of microscopic
involvement. We explore the following hypothesis: Can acceptable locoregional disease
control be obtained with less treatment-related morbidity by focusing RT on regions of gross
disease, sparing regions with a low risk of harboring subclinical disease from elective RT?